MedTrace Logo

Remifentanil for the I-gel and Laryngeal Mask Airway Insertion

NCT02382354 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2015-10-14

No results posted yet for this study

Summary

Structural differences of supraglottic airway devices could influence the different compressive forces in the oropharyngeal cavities, and require different depth of anesthesia. The addition of remifentanil during propofol anesthesia facilitates the insertion of laryngeal mask airway (LMA) with minimal adverse hemodynamic disturbances. This study was designed to determine the effect-site concentration of remifentanil in 50% of patients (EC50) and 95% of patients (EC95) for successful i- gel insertion, and compare those for LMA insertion during propofol target-controlled infusion (TCI).

Conditions

  • Supraglottic Airways for General Anesthesia

Interventions

DRUG

remifentanil

The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method

DEVICE

i-gel

I-gel insertion was inserted 5 min after anesthesia induction

DEVICE

laryngeal mask airway

laryngeal mask airway insertion was inserted 5 min after anesthesia induction

DRUG

propofol

Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml

Sponsors & Collaborators

  • Ajou University School of Medicine

    lead OTHER

Principal Investigators

  • Jong Yeop Kim, MD · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02382354 on ClinicalTrials.gov